Hydroxyethylrutoside
Hydroxyethylrutosides (oxerutins, O-beta-hydroxyethyl-rutosides, HR, or HER) are hydroxyethyl derivatives of rutosides. Examples include:
Oxerutins are semisynthetic derivatives of plant constituents. Although they are closely related to the natural flavonoid rutin, hydroxyethylrutosides are not found in food. The only way to take them is in a supplement.[1]
Health benefits
[edit] | This section needs more reliable medical references for verification or relies too heavily on primary sources. (February 2019) |  |
Relvène (1967 French version), Venoruton (1962 Swiss version), and Paroven are mixtures of hydroxyethyl rutinosides. Hydroxyethylrutosides are used in the treatment of chronic venous insufficiency[2] and hypertensive microangiopathy.[3] Oxerutins work by reducing leakage from the small blood vessels (capillaries).[4]
Hydroxyethylrutosides have been used as an alternative to horse chestnut preparations (venostasin) containing aescin. Typical doses are in the order of 1,000 mg/day.[5]
Effects of hydroxyethylrutosides against adriamycin-induced toxicity have been investigated in rats.[6]
References
[edit]- ^ Oxerutins on healthlibrary.epnet.com
- ^ Frick, RW (2000). "Three treatments for chronic venous insufficiency: Escin, hydroxyethylrutoside, and Daflon". Angiology. 51 (3): 197–205. doi:10.1177/000331970005100303. PMID 10744007. S2CID 19421726.
- ^ Incandela, L; Belcaro, G; Renton, S; Desanctis, MT; Cesarone, MR; Bavera, P; Ippolito, E; Bucci, M; et al. (2002). "HR (Paroven, Venoruton; 0-(beta-hydroxyethyl)-rutosides) in venous hypertensive microangiopathy: A prospective, placebo-controlled, randomized trial". Journal of Cardiovascular Pharmacology and Therapeutics. 7 (Suppl 1): S7–S10. doi:10.1177/107424840200700103. PMID 12011966. S2CID 9720685.
- ^ Paroven on netdoctor.co.uk
- ^ The handbook of clinically tested herbal remedies, Volume 2 by Marilyn Barrett
- ^ Gulati, OP; Nordmann, H; Aellig, A; Maignan, MF; McGinness, J (1985). "Protective effects of O-(beta-hydroxyethyl)-rutosides (HR) against adriamycin-induced toxicity in rats". Archives Internationales de Pharmacodynamie et de Thérapie. 273 (2): 323–34. PMID 4004421.